ecrin-mdr-crcClinical2004AdenocarcinomaAdenocarcinoma of the gallbladderCancerAdenocarcinomaAdenocarcinoma Of The GallbladderCancerInterventionalhttps://newmdr.ecrin.org/Study/2012157United States12Stage IV prostate cancerRecurrent colon cancerStage IVB cervical cancerRecurrent bladder cancerAdenocarcinoma of the rectumRecurrent rectal cancerRecurrent breast cancerRecurrent renal cell cancerRecurrent pancreatic cancerAdenocarcinoma of the bladderRecurrent vaginal cancerAdenocarcinoma of the prostateStage IV salivary gland cancerAdenocarcinoma of the lungUnresectable extrahepatic bile duct cancerVaginal clear cell adenocarcinomaRecurrent extrahepatic bile duct cancerRecurrent esophageal cancerStage IV esophageal cancerStage IVB vaginal cancerStage IV bladder cancerStage IV non-small cell lung cancerStage IV rectal cancerOvarian mucinous cystadenocarcinomaStage IV breast cancerRecurrent gastric cancerCervical adenocarcinomaRecurrent gallbladder cancerAdenocarcinoma of the pancreasAdenocarcinoma of the colonStage IVA vaginal cancerSmall intestine adenocarcinomaOvarian serous cystadenocarcinomaRecurrent endometrial carcinomaOvarian clear cell cystadenocarcinomaStage IV pancreatic cancerStage IV endometrial carcinomaAntibodiesStage IVA cervical cancerOvarian endometrioid adenocarcinomaStage IV colon cancerUnresectable gallbladder cancerStage IV gastric cancerAdenocarcinoma of the esophagusRecurrent cervical cancerStage IV renal cell cancerRecurrent prostate cancerRecurrent ovarian epithelial cancerRecurrent non-small cell lung cancerOvarian undifferentiated adenocarcinomaVaginal adenocarcinomaAntibodies, MonoclonalAdenocarcinoma of the stomachAdenocarcinoma with squamous metaplasia of the gallbladderSalivary gland adenocarcinomaAdenocarcinoma of the extrahepatic bile ductRecurrent small intestine cancerEndometrial adenocarcinomaRecurrent salivary gland cancerStage IV ovarian epithelial cancerECRIN MDRCompletedfalseRAV12 in Treating Patients With Metastatic or Recurrent AdenocarcinomaRATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of RAV12 in treating patients with metastatic or recurrent adenocarcinoma.2004-12-152012157NCT00101972